Clinical Trials

Finding the right clinical trials should not be an overwhelming endeavor for patients. Explore how navigator training can simplify trial discussions and support patient-centered decision-making.

In their expert commentaries, Jackie Broadway-Duren, PhD, DNP, APRN, FNP-BC, FAANP, and Mollie Moran, APRN-CNP, examine the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, pirtobrutinib, in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Learn how the Virtual Research Nurse framework is breaking down barriers to clinical trial access in underserved community oncology practices.

Discover how patient navigation and technology are breaking barriers to clinical trial access and fostering equity and inclusion in cancer research for underserved communities.

A CATCH is a navigation success story where a navigation tactic improved a patient’s situation. This month, we profile a navigator who used her bilingual skills to help a Latina patient with triple-negative breast cancer successfully enroll in a phase 3 clinical trial.

A peer navigation model that addresses barriers to diverse participation and aims to boost enrollment in childhood cancer therapeutic clinical trials is underway and was presented by one of the study researchers at the 66th Annual Meeting of the American Society of Hematology, held in San Diego, CA.

We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Virginia F. Borges, MD, MMSc, on the use of abemaciclib as a combination or monotherapy in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer.

In their expert commentaries, Katherine Tobon, PharmD, BCOP, and Jiajoyce Richardson, DNP, CRNP, examine the role of Bruton tyrosine kinase (BTK) inhibitors, with a particular emphasis on pirtobrutinib, in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). They provide a thorough review of the BRUIN study, concentrating on the safety profile and therapeutic efficacy of pirtobrutinib in patients with CLL or SLL who have previously received at least 1 BTK inhibitor.

In this fourth installment of a 5-part series, the authors provide tools for navigators to effectively guide patients through the clinical trial experience, with a focus on molecular profiling and genetic testing.